exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088573 RNA Name: hsa-miR-4508 RNA Type: miRNA Chromosome: chr15 Starnd: - Coordinate: Start Site(bp): 23562107 End Site(bp): 23562123 External Links: hsa-miR-4508

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand USP22 chr17 20999596 21043760 - AC005943.1 chr19 1578339 1605445 - ADNP2 chr18 80109262 80147523 + ANAPC1 chr2 111611639 111884690 - ANKRD54 chr22 37830855 37849327 - CDC42BPB chr14 102932380 103057549 - COA1 chr7 43608456 43729717 - CSNK1G2 chr19 1941172 1981338 + CTC1 chr17 8224815 8248056 - EID2 chr19 39538707 39540161 - ESYT2 chr7 158730995 158830253 - FUS chr16 31180110 31194871 + LTBP3 chr11 65538805 65558930 - MBD3 chr19 1573596 1592865 - NDUFB4 chr3 120596328 120602507 + OXTR chr3 8750408 8769628 - PROB1 chr5 139390592 139395104 - SCAF4 chr21 31671000 31732118 - SLBP chr4 1692731 1712344 - TM9SF1 chr14 24189149 24195687 - TMCO3 chr13 113491021 113554590 + UBE3A chr15 25333728 25439051 - URI1 chr19 29923644 30016612 + UROS chr10 125784980 125823258 - USP28 chr11 113797874 113875570 - WRAP53 chr17 7686071 7703502 + ZNF580 chr19 55635016 55643470 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand HCG18 chr6 30286690 30327382 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.